INCPF (InnoCare Pharma) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INCPF InnoCare Pharma Ltd INCPF
83 GF Score
Price $1.55
GF Value $2.32
! 7 Warning Signs
View Full Analysis

What is InnoCare Pharma Net Loan?

Net Loan only applies to banks and insurance companies.

INCPF
83GF Score
InnoCare Pharma Ltd INCPF
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is InnoCare Pharma (INCPF) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued. The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.

Key valuation signals for INCPF:

  • Net Loan:
  • GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InnoCare Pharma Business Description

Address No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score

Get the complete analysis for INCPF

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price
$2.32
GF Value